Alzheimer's Disease
Conditions
Keywords
Aducanumab, BIIB037
Brief summary
The primary objective of this study is to evaluate the safety and tolerability of multiple doses of Aducanumab (recombinant, fully human anti-Aβ IgG1 mAb) in participants with prodromal or mild Alzheimer's Disease (AD). The secondary objectives of this study are to assess the effect on cerebral amyloid plaque content as measured by florbetapir-fluorine-18 (18F-AV-45F-AV-45) positron emission tomography (PET) imaging, to assess the multiple dose serum concentrations of Aducanumab and to evaluate the immunogenicity of Aducanumab after multiple dose administration in this population.
Detailed description
The study consists of a placebo-controlled period to study week 54, followed by a long-term extension to study week 518. The placebo-controlled period is conducted with a staggered, parallel group design, with the first 3 treatment arms conducted in parallel, 2 further treatment arms subsequently beginning in parallel, 2 additional treatment arms beginning in parallel, and the last 2 treatment arms subsequently beginning in parallel. Qualifying participants can enter the long-term extension period for up to 42 additional doses of active drug for the first 3 years of LTE. Furthermore, up until the last participant in Arms 8 and 9 has had his or her last dose in the fifth year of the LTE, eligible participants will be able to continue treatment beyond the third year of the LTE.
Interventions
DRUGAducanumab (recombinant, fully human anti-Aβ IgG1 mAb)
Participants will receive an infusion of Aducanumab on Days 1, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, 337, and 365 (±2 days) at the study clinic and assigned does levels. The infusion will be administered for approximately 1 hour. The study is conducted with a staggered, parallel group design, with the first 3 treatment arms conducted in parallel, 2 further treatment arms subsequently beginning in parallel and the 2 last treatment arms subsequently beginning in parallel. Qualifying participants can enter the long-term extension period at doses described in the treatment arms for up to an additional 112 doses.
DRUGPlacebo
Placebo to mimic the low dose, mid-dose and high-dose treatment arms of the experimental intervention; administered by intravenous (IV) infusion on Days 1, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, 337, and 365 (±2 days) at the study clinic. Qualifying participants can enter the long-term extension period at doses described in the treatment arms for up to an additional 112 doses.
Sponsors
Biogen
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
50 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
Key Inclusion Criteria: * Participants must be ambulatory. * Participants must meet the following core clinical criteria as determined by the Investigator: Prodromal Alzheimer's Disease (AD) (all of the criteria must apply): * Mini Mental State Examination (MMSE) scores between 24-30 (inclusive) * a spontaneous memory complaint * objective memory loss defined as a free recall score of ≤27 on the Free and Cued Selective Reminding Test (FCSRT) * a global Clinical Dementia Rating Scale (CDR) score of 0.5 * absence of significant levels of impairment in other cognitive domains * essentially preserved activities of daily living, and an absence of dementia. OR Mild Alzheimer's Disease (AD) criteria (all criteria must apply): * Mini Mental State Examination (MMSE) scores between 20-26 (inclusive) * a global Clinical Dementia Rating Scale (CDR) of 0.5 or 1.0 * meeting the National Institute on Aging-Alzheimer's Association core clinical criteria for probable AD. * Participants must have a positive florbetapir positron emission tomography (PET) amyloid scan. * Participants must consent to apolipoprotein E (ApoE) genotyping. * Apart from clinical diagnosis of Alzheimer's Disease (AD), participant must be in good health. * Must have a reliable informant or caregiver. Key
Exclusion criteria
* Any medical or neurological condition (other than Alzheimer's Disease) that might be a contributing cause of the participant's cognitive impairment. * Have had a stroke or Transient Ischemic Attack (TIA) or unexplained loss of consciousness in the past 1 year. * Clinically significant psychiatric illness in past 6 months. * Seizure in the past 3 years. * Poorly controlled diabetes mellitus. * History of unstable angina, myocardial infarction, chronic heart failure, or clinical significant conduction abnormalities within 1 year prior to Screening. * Indication of impaired renal or liver function. * Have human immunodeficiency virus (HIV) infection. * Have a significant systematic illness or infection in past 30 days. * Brain MRI showing evidence of acute or sub-acute micro or macrohemorrhage, greater than 4 microhemorrhages, cortical infarct or greater than one 1 lunar infarct. * Any contraindications to brain MRI or positron emission tomography (PET) scans. * Negative positron emission tomography (PET) scan with any amyloid-targeting ligand within 48 weeks of Screening. * Clinically significant 12-lead electrocardiogram (ECG) abnormalities. * Alcohol or substance abuse in past 1 year. * Taking blood thinners (except for aspirin at a prophylactic dose or less) * Have changes in medications or doses of medication in past 4 weeks. NOTE: Other protocol defined Inclusion/
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of Participants with Adverse Events | Baseline to week 518 |
Secondary
| Measure | Time frame |
|---|---|
| Change from baseline in florbetapir-fluorine-18 (18F-AV-45F-AV-45) positron emission tomography (PET) imaging in certain brain areas. | Day 1, Weeks 26, 54, End of year 2, 3, and 4 |
| Multiple dose pharmacokinetic (PK) serum concentrations of Aducanumab | Up to week 518 |
| Change from Baseline in Incidence of Anti-Aducanumab Antibodies in Serum. | Up to week 518 |
Countries
United States
Outcome results
None listed